Tabowei Godfrey, Dadzie Samuel K, Khoso Ashique Ali, Riyalat Abdallah A, Ali Muhammad, Atta Mohamed Ismael Mohamed Samir Ismael, Wei Calvin R, Ali Neelum
Internal Medicine, Texas Tech University Health Sciences Center, Odessa, USA.
Internal Medicine, Piedmont Athens Regional Medical Center, Athens, USA.
Cureus. 2024 Oct 24;16(10):e72276. doi: 10.7759/cureus.72276. eCollection 2024 Oct.
This meta-analysis compared the efficacy of intraosseous (IO) versus intravenous (IV) drug administration in out-of-hospital cardiac arrest (OHCA). We systematically searched Embase, Web of Science, PubMed, and Cochrane Library through September 20, 2024, for relevant studies. The primary outcome was favorable neurological outcome, with secondary outcomes, including survival to hospital discharge and return of spontaneous circulation (ROSC). Seventeen studies, including randomized controlled trials and observational studies, were included in the final analysis. Pooled results showed that IV access was associated with significantly better outcomes compared to IO access. Patients in the IV group had 1.73 times higher odds of favorable neurological outcomes (RR: 1.73, 95% CI: 1.32-2.27), 1.64 times higher odds of survival to hospital discharge (RR: 1.64, 95% CI: 1.27-2.12), and 1.27 times higher odds of ROSC (RR: 1.27, 95% CI: 1.16-1.40). However, significant heterogeneity was observed across studies for all outcomes. These findings suggest that IV access may be superior to IO access in improving outcomes for OHCA patients. However, the high heterogeneity and conflicting results from individual studies highlight the need for careful interpretation and further research. Factors such as ease of access, speed of establishment, and patient condition should also be considered when choosing between IV and IO routes during resuscitation. This meta-analysis underscores the importance of reassessing current guidelines and conducting more robust primary studies to optimize vascular access strategies in OHCA management.
这项荟萃分析比较了在院外心脏骤停(OHCA)中骨内(IO)给药与静脉(IV)给药的疗效。我们系统检索了截至2024年9月20日的Embase、Web of Science、PubMed和Cochrane图书馆,以查找相关研究。主要结局是良好的神经功能结局,次要结局包括存活至出院和自主循环恢复(ROSC)。最终分析纳入了17项研究,包括随机对照试验和观察性研究。汇总结果显示,与骨内通路相比,静脉通路与显著更好的结局相关。静脉组患者获得良好神经功能结局的几率高1.73倍(RR:1.73,95%CI:1.32-2.27),存活至出院的几率高1.64倍(RR:1.64,95%CI:1.27-2.12),自主循环恢复的几率高1.27倍(RR:1.27,95%CI:1.16-1.40)。然而,所有结局在各研究中均观察到显著的异质性。这些发现表明,在改善OHCA患者结局方面,静脉通路可能优于骨内通路。然而,高异质性和个别研究结果相互矛盾凸显了谨慎解读和进一步研究的必要性。在复苏期间选择静脉和骨内途径时,还应考虑通路的难易程度、建立速度和患者状况等因素。这项荟萃分析强调了重新评估现行指南以及开展更有力的原始研究以优化OHCA管理中血管通路策略的重要性。